Legend Biotech's core business model centers on a differentiated CAR-T therapy with strong clinical data and expanding commercial scale. The company benefits from strategic partnerships that bolster manufacturing capacity and market reach, which is critical in this capital-intensive sector. Growth …
Legend Biotech (LEGN) Q4 2024: CARVYKTI Sales Surge 110%, Doubling Capacity to Drive 2025 Growth
Legend Biotech’s CARVYKTI continues to lead the multiple myeloma CAR-T market with accelerating sales and expanding manufacturing capacity. The company’s strategic investments in commercial infrastructure and pipeline development position it for operational profitability in 2026 and sustained growth beyond.
Summary
- Market Leadership Solidified: CARVYKTI’s unique clinical profile drives rapid adoption in earlier treatment lines.
- Capacity Expansion Underway: Manufacturing scale-up with Novartis and Belgian facilities supports growing demand.
- Pipeline Momentum: Early-stage programs targeting solid tumors and autoimmune diseases signal long-term growth potential.
Business Overview
Legend Biotech is a global leader in cell therapy, specializing in chimeric antigen receptor T-cell (CAR-T) treatments for multiple myeloma and other cancers. The company generates revenue primarily through collaboration agreements, license fees, and sales of its lead product CARVYKTI, developed and commercialized with Johnson & Johnson (J&J). Key business segments include CARVYKTI commercial sales, research and development (R&D) programs in hematologic and solid tumors, and manufacturing partnerships, notably with Novartis.
Performance Analysis
In the fourth quarter of 2024, Legend Biotech reported approximately $334 million in net trade sales of CARVYKTI, representing a 110% year-over-year increase and a 17% sequential rise from the prior quarter. This growth was driven by expanding demand, capacity ramp-up, and the CARTITUDE-4 label launch enabling use in second-line multiple myeloma patients. International sales also surged 138% year-over-year to $31 million, reflecting European market expansion and reimbursement progress in Spain.
Revenue for the quarter totaled $187 million, including $168 million in collaboration revenue from CARVYKTI sales and $18 million in license revenue from the Novartis agreement for DLL3-targeted CAR-T therapies. Operating expenses rose in line with commercial expansion, with collaboration cost of revenue increasing to $69 million and selling and distribution expenses growing to $49 million due to sales force expansion and second-line indication launch. Despite these investments, the company reported a net income of $26 million for the quarter, benefiting from a substantial $110 million unrealized foreign exchange gain related to currency fluctuations in its treasury operations.
- Revenue Mix Shift: Nearly 60% of CARVYKTI sales now derive from second to fourth-line treatment, underscoring successful penetration of earlier patient populations.
- Outpatient Administration Growth: Over half of CARVYKTI treatments occur in outpatient settings, leveraging its delayed cytokine release syndrome onset to improve patient experience and treatment center capacity.
- Balance Sheet Strength: $1.1 billion in cash and equivalents secures financial runway through mid-2026, supporting ongoing R&D and manufacturing investments.
Overall, Legend Biotech demonstrated robust commercial execution and operational scalability, setting the stage for accelerated growth in 2025 as new manufacturing sites come online and label expansion efforts continue.
Executive Commentary
"CARVYKTI is the fastest-launched CAR T therapy. The achievements of our global teams have set us up for great success in 2025, and we are poised to provide CARVYKTI to even more patients around the world."
Ying Kuang, Chief Executive Officer
"We generated approximately $334 million in total net sales for CARVYKTI during the fourth quarter, an increase of 110% year-over-year. Our profitability guidance implies further growth acceleration, showing good progress towards our long-term goals."
Jesse Young, Interim Chief Financial Officer
Strategic Positioning
1. Expanding CARVYKTI Market Penetration
Legend Biotech is successfully shifting CARVYKTI use into earlier lines of therapy, with nearly 60% of sales now in second to fourth-line settings. This transition is supported by positive Phase III data demonstrating superior minimal residual disease negativity and overall survival benefits. The company’s commercial strategy targets over 8,000 hematologists and 3,000 clinics, emphasizing community oncology adoption to broaden patient access.
2. Manufacturing Capacity Scale-Up
To meet growing demand, Legend is doubling CARVYKTI supply in 2025 through capacity expansion at multiple sites. The Novartis commercial manufacturing facility in New Jersey recently received FDA approval and began production, contributing meaningfully starting in Q2 2025. Additionally, the TechLand facility in Ghent, Belgium, is ramping up to support European markets, with further expansion approved through 2028, signaling confidence in sustained demand growth.
3. Outpatient Treatment Leadership
CARVYKTI’s delayed onset of cytokine release syndrome enables a majority of treatments to occur in outpatient settings, enhancing patient convenience and optimizing treatment center resources. This outpatient advantage differentiates CARVYKTI from competing therapies and supports scalability as more centers gain experience and FACT accreditation through affiliations.
4. Clinical Pipeline Diversification
Beyond multiple myeloma, Legend is advancing early-stage CAR-T programs targeting solid tumors such as pancreatic and small cell lung cancers, as well as autoimmune diseases. Dose escalation readouts and biomarker data are expected in 2025, underscoring the company’s commitment to innovation and long-term growth beyond its lead product.
5. Risk Mitigation and Safety Optimization
Legend is actively incorporating absolute lymphocyte count (ALC) monitoring and dexamethasone prophylaxis in ongoing trials to mitigate neurotoxicity risks associated with CAR-T therapy. Collaboration with academic centers and investigator-initiated trials aim to refine safety protocols, facilitating broader outpatient use and reinforcing CARVYKTI’s positive benefit-risk profile.
Key Considerations
Legend Biotech’s Q4 results highlight the interplay between clinical differentiation, manufacturing scale, and commercial execution in driving CARVYKTI’s market leadership. Key strategic points include:
- Capacity Constraints Easing: Manufacturing expansions should alleviate supply bottlenecks by year-end, enabling demand to be fully met and supporting revenue acceleration.
- Community Penetration Critical: Deepening education and referral networks among community oncologists is essential to sustain growth in earlier treatment lines.
- Competitive Landscape: Upcoming BCMA bispecific therapies may introduce competition in 2026, but Legend’s established efficacy, durability, and one-time treatment convenience offer durable advantages.
- Financial Discipline: R&D spending remains controlled despite commercial growth, with anticipated shifts in investment focus post-2026 as BCMA programs mature.
- Foreign Exchange Volatility: Unrealized currency gains contributed significantly to reported net income, underscoring the importance of adjusted net loss metrics for operational performance assessment.
Risks
Legend faces risks from potential supply chain disruptions, regulatory delays, and competitive pressures, especially with emerging CAR-T and bispecific therapies targeting similar indications. Currency fluctuations continue to create volatility in reported earnings. Additionally, broader adoption of outpatient administration depends on successful implementation of safety mitigation protocols and FACT accreditation processes.
Forward Outlook
For Q1 2025, Legend expects modest sequential revenue growth due to seasonality and facility maintenance, with stronger acceleration anticipated in Q2 and throughout the second half of the year as new manufacturing capacity from Novartis and Belgian facilities comes online. The company maintains confidence in doubling CARVYKTI supply in 2025 and projects operational profitability excluding unrealized foreign exchange effects by 2026.
- Q1 2025: Modest sequential sales growth expected.
- Full Year 2025: Doubling of CARVYKTI supply and accelerating revenue growth.
- 2026: Anticipated operational profitability and continued market expansion.
Management emphasizes ongoing investments in manufacturing, commercial infrastructure, and clinical programs to sustain growth momentum and maximize CARVYKTI’s market potential.
Takeaways
Legend Biotech’s Q4 performance underscores the company’s leadership in multiple myeloma CAR-T therapy, driven by a differentiated product profile and strategic capacity expansion. Investors should monitor:
- Commercial Execution: Continued shift of CARVYKTI use into earlier lines and outpatient settings will be key growth drivers.
- Manufacturing Scale: Successful ramp-up of Novartis and TechLand facilities is critical to meeting demand and supporting revenue acceleration.
- Pipeline Progress: Early clinical readouts in solid tumors and autoimmune diseases will indicate the company’s ability to diversify beyond BCMA-targeted therapies.
Conclusion
Legend Biotech’s fourth quarter results demonstrate robust commercial growth and operational scaling of CARVYKTI, positioning the company for profitability in 2026. Strategic investments in manufacturing and pipeline development support a compelling long-term growth trajectory despite competitive and operational challenges.
Industry Read-Through
Legend’s success in rapidly expanding CARVYKTI’s market penetration and outpatient administration provides a blueprint for CAR-T commercialization in hematologic malignancies. The company’s approach to safety mitigation and manufacturing scale-up offers insights for peers developing cell therapies facing similar operational complexities. The upcoming competitive dynamics with bispecific antibodies highlight the evolving treatment landscape in multiple myeloma, emphasizing the importance of clinical differentiation and patient-centric delivery models across the sector.